Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria F Camargo

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Pharmaceutics|April 3, 2021
Tumor Activated Cell Penetrating Peptides to Selectively Deliver Immune Modulatory DrugsDina V Hingorani, Maria F Camargo, Maryam A Quraishi, et al.
Biorxiv : the Preprint Server for Biology|February 6, 2026
Orthogonally targeted tumor radiosensitization using cell penetrating peptide-ATM inhibitor conjugates to stimulate anti-tumor immune responsesKanika Dhawan, Michael M Allevato, Jacqueline Lesperance, et al.
Cancer Discovery|September 13, 2017
Galectin-3, a Druggable Vulnerability for KRAS-Addicted CancersLaetitia Seguin, Maria F Camargo, Hiromi I Wettersten, et al.
Cancer Letters|June 19, 2026
Orthogonally targeted tumor radiosensitization using cell penetrating peptide-ATM inhibitor conjugates to stimulate anti-tumor immune responsesKanika Dhawan, Michael M Allevato, Jacqueline Lesperance, et al.
Molecular Cancer Therapeutics|October 11, 2019
Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell PermeabilityDina V Hingorani, Matthew K Doan, Maria F Camargo, et al.
Molecules (Basel, Switzerland)|December 17, 2024
Tumor-Targeted Cell-Penetrating Peptides Reveal That Monomethyl Auristatin E Temporally Modulates the Tumor Immune MicroenvironmentMahsa Mortaja, Marcus M Cheng, Alina Ali, et al.
Biomaterials|April 19, 2020
Redirecting extracellular proteases to molecularly guide radiosensitizing drugs to tumorsDina V Hingorani, Jessica L Crisp, Matthew K Doan, et al.
Plos One|December 22, 2006
A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancerClaudia Arce, Carlos Pérez-Plasencia, Aurora González-Fierro, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|October 24, 2025
Interactions of Antibody Drug Conjugate Anti-Tubulin and Topoisomerase I Inhibitor Payloads with Radiotherapy to Potentiate ImmunotherapyJacqueline Lesperance, Bryan S Yung, Michael M Allevato, et al.
Nature Communications|July 5, 2022
Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapyDina V Hingorani, Michael M Allevato, Maria F Camargo, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Pharmaceutics|April 3, 2021
Tumor Activated Cell Penetrating Peptides to Selectively Deliver Immune Modulatory DrugsDina V Hingorani, Maria F Camargo, Maryam A Quraishi, et al.
Biorxiv : the Preprint Server for Biology|February 6, 2026
Orthogonally targeted tumor radiosensitization using cell penetrating peptide-ATM inhibitor conjugates to stimulate anti-tumor immune responsesKanika Dhawan, Michael M Allevato, Jacqueline Lesperance, et al.
Cancer Discovery|September 13, 2017
Galectin-3, a Druggable Vulnerability for KRAS-Addicted CancersLaetitia Seguin, Maria F Camargo, Hiromi I Wettersten, et al.
Cancer Letters|June 19, 2026
Orthogonally targeted tumor radiosensitization using cell penetrating peptide-ATM inhibitor conjugates to stimulate anti-tumor immune responsesKanika Dhawan, Michael M Allevato, Jacqueline Lesperance, et al.
Molecular Cancer Therapeutics|October 11, 2019
Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell PermeabilityDina V Hingorani, Matthew K Doan, Maria F Camargo, et al.
Molecules (Basel, Switzerland)|December 17, 2024
Tumor-Targeted Cell-Penetrating Peptides Reveal That Monomethyl Auristatin E Temporally Modulates the Tumor Immune MicroenvironmentMahsa Mortaja, Marcus M Cheng, Alina Ali, et al.
Biomaterials|April 19, 2020
Redirecting extracellular proteases to molecularly guide radiosensitizing drugs to tumorsDina V Hingorani, Jessica L Crisp, Matthew K Doan, et al.
Plos One|December 22, 2006
A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancerClaudia Arce, Carlos Pérez-Plasencia, Aurora González-Fierro, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|October 24, 2025
Interactions of Antibody Drug Conjugate Anti-Tubulin and Topoisomerase I Inhibitor Payloads with Radiotherapy to Potentiate ImmunotherapyJacqueline Lesperance, Bryan S Yung, Michael M Allevato, et al.
Nature Communications|July 5, 2022
Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapyDina V Hingorani, Michael M Allevato, Maria F Camargo, et al.
Pageof 2